港股详情

本页面由Tiger Fintech (Singapore) Pte. Ltd.提供服务

维升药业-B

40.940

-0.580-1.40%

成交量：3.12万

成交额：126.93万

市值：46.67亿

市盈率：-21.04

高：41.480

开：41.400

低：40.200

收：41.520

52周最高：69.150

52周最低：39.250

股本：1.14亿

香港流通股本：1.14亿

量比：0.99

换手率：0.03%

股息：- -

股息率：- -

每股收益(LYR):-1.946

净资产收益率：-57.66%

总资产收益率：-29.52%

市净率：5.00

市盈率(LYR):-21.04

市销率: 5090.88

数据加载中...

总览公司新闻公告

维升药业-B(02561)：陆楹已获委任为首席财务官

维升药业-B10月13日主力净流出23.9万元散户资金买入

维升药业-B10月09日主力净流出51.8万元散户资金买入

维升药业-B午前涨超3% 隆培促生长素有望年内获批上市

创新药全链条高景气持续，维升药业-B(02561)或迎“戴维斯双击”

维升药业-B09月23日遭主力抛售21.5万元

大摩：市场对生物科技股认可度提升推动股价跑赢大市看好康方生物(09926)等

维升药业-B09月22日主力净流出57.1万元散户资金买入

维升药业-B09月16日主力净流入90.1万元散户资金抛售

横盘迷雾下的价值火山：维升药业-B（2561.HK）正站在价值重构临界点

长效生长激素“元年”启幕，从“日剂”到“周剂”百亿市场竞争格局生变

维升药业-B(02561)发布中期业绩研究及开发成本4662.1万元同比增加19.8%

Ascendis 上半年产品收入大涨 155%，维升药业拥有国内权益

Insight数据库

维升药业-B07月31日遭主力抛售37.4万元

维升药业－Ｂ(02561)股价上升5.07%，现价港币$52.85

阿斯达克财经

用于成人！长效生长激素获 FDA 批准上市，维升药业拥有国内权益

Insight数据库

维升药业-B07月28日主力净流入99.8万元散户资金抛售

维升药业-B07月22日主力净流出32.9万元散户资金买入

维升药业-B(02561)携手安科生物加速长效生长激素中国商业化进程

“IPO盛宴”强势回归

艾美达医药咨询

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/stock/02561/news"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"02561","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02561\",,,,,undefined,":{"symbol":"02561","market":"HK","secType":"STK","nameCN":"维升药业-B","latestPrice":40.94,"timestamp":1760342239125,"preClose":41.52,"halted":0,"volume":31200,"delay":0,"floatShares":113999999,"shares":113999999,"eps":-1.946273,"marketStatus":"未开盘","change":-0.58,"latestTime":"10-13 15:57:19","open":41.4,"high":41.48,"low":40.2,"amount":1269286,"amplitude":0.030829,"askPrice":41,"askSize":500,"bidPrice":40.5,"bidSize":1500,"shortable":0,"etf":0,"ttmEps":-2.238552,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1760405400000},"marketStatusCode":0,"adr":0,"listingDate":1742486400000,"exchange":"SEHK","adjPreClose":41.52,"openAndCloseTimeList":[[1760319000000,1760328000000],[1760331600000,1760342400000]],"volumeRatio":0.9867172656798534,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02561\",,,,,undefined,":{"symbol":"02561","floatShares":113999999,"roa":"-29.52%","roe":"-57.66%","lyrEps":-1.946273,"volumeRatio":0.9867172656798534,"shares":113999999,"dividePrice":0,"high":41.48,"amplitude":0.030829,"preClose":41.52,"low":40.2,"week52Low":39.25,"pbRate":"5.00","psRate":"5090.88","week52High":69.15,"institutionHeld":0,"latestPrice":40.94,"committee":0.5,"eps":-1.946273,"divideRate":0,"volume":31200,"delay":0,"ttmEps":-2.238552,"open":41.4,"prevYearClose":68.8,"prevWeekClose":41.52,"prevMonthClose":42.5,"prevQuarterClose":42.5,"fiveDayClose":43.46,"twentyDayClose":44.86,"sixtyDayClose":47.2},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/02561\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"02561\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"02561\",market:\"HK\",delay:false,,,undefined,":{"strongBuy":0.5,"buy":0.5,"hold":0,"sell":0,"strongSell":0,"meanLabel":"STRONG BUY","meanPercent":0.5,"analysts":2,"updateTime":1746460800000},"@#url:\"https://hq.skytigris.cn/hkstock/value_analysis/stock/02561\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"02561","date":"2025-10-10","current":-18.288608,"percent":0.961832,"low":-30.760225,"twenty":-27.909584,"median":-26.722604,"eighty":-23.450061,"high":-17.514985,"avg":-25.781984,"sd":2.978127,"marketCap":4360487033},"quantilePoints":[{"date":"2025-04-03","current":-21.475965,"twenty":-22.637245,"median":-22.569747,"eighty":-22.098421,"marketCap":5724824916},{"date":"2025-04-11","current":-18.134639,"twenty":-22.558476,"median":-18.349759,"eighty":-18.045823,"marketCap":4802017317},{"date":"2025-04-17","current":-25.787715,"twenty":-25.955056,"median":-22.513392,"eighty":-18.141011,"marketCap":4682394110},{"date":"2025-04-25","current":-29.965674,"twenty":-27.695216,"median":-22.653961,"eighty":-18.190408,"marketCap":5445704099},{"date":"2025-05-02","current":-28.244363,"twenty":-27.861811,"median":-26.066617,"eighty":-18.349759,"marketCap":5143797909},{"date":"2025-05-09","current":-27.581562,"twenty":-28.248468,"median":-27.028836,"eighty":-20.850724,"marketCap":5058352761},{"date":"2025-05-16","current":-27.481285,"twenty":-28.307048,"median":-27.470681,"eighty":-22.305907,"marketCap":5081138134},{"date":"2025-05-23","current":-29.180898,"twenty":-28.483617,"median":-27.481285,"eighty":-22.603559,"marketCap":5411526040},{"date":"2025-05-30","current":-27.585218,"twenty":-28.483617,"median":-27.495492,"eighty":-22.648389,"marketCap":5138101566},{"date":"2025-06-06","current":-26.147365,"twenty":-28.307048,"median":-27.481285,"eighty":-24.987287,"marketCap":5212154028},{"date":"2025-06-13","current":-28.707887,"twenty":-28.307048,"median":-27.486097,"eighty":-25.744296,"marketCap":5724824916},{"date":"2025-06-20","current":-27.87701,"twenty":-28.483617,"median":-27.500076,"eighty":-26.010837,"marketCap":5548238276},{"date":"2025-06-27","current":-26.600431,"twenty":-28.46744,"median":-27.491566,"eighty":-26.131215,"marketCap":5308991862},{"date":"2025-07-04","current":-25.999842,"twenty":-28.345085,"median":-27.470681,"eighty":-26.039907,"marketCap":5189368655},{"date":"2025-07-11","current":-25.483255,"twenty":-28.252573,"median":-27.442177,"eighty":-25.700877,"marketCap":5081138134},{"date":"2025-07-18","current":-27.275886,"twenty":-28.168194,"median":-27.211053,"eighty":-25.700877,"marketCap":5434311412},{"date":"2025-07-25","current":-27.917728,"twenty":-28.10544,"median":-27.177054,"eighty":-25.808828,"marketCap":5582416336},{"date":"2025-08-01","current":-26.858726,"twenty":-28.252573,"median":-27.236899,"eighty":-25.835301,"marketCap":5337473578},{"date":"2025-08-08","current":-26.45431,"twenty":-28.168194,"median":-27.174901,"eighty":-25.937332,"marketCap":5270256728},{"date":"2025-08-15","current":-27.513449,"twenty":-28.142473,"median":-27.236899,"eighty":-26.012565,"marketCap":5473046546},{"date":"2025-08-22","current":-26.703746,"twenty":-28.118557,"median":-27.177054,"eighty":-26.021282,"marketCap":5295320638},{"date":"2025-08-29","current":-26.119434,"twenty":-28.10544,"median":-27.144467,"eighty":-26.021282,"marketCap":5204179147},{"date":"2025-09-05","current":-23.791598,"twenty":-28.093765,"median":-27.114576,"eighty":-25.835301,"marketCap":4735670561},{"date":"2025-09-12","current":-23.381705,"twenty":-28.083375,"median":-27.05699,"eighty":-25.694259,"marketCap":4662460107},{"date":"2025-09-19","current":-23.051901,"twenty":-28.060478,"median":-27.021811,"eighty":-25.478949,"marketCap":4593433106},{"date":"2025-09-26","current":-21.933119,"twenty":-28.003961,"median":-26.881441,"eighty":-23.835003,"marketCap":4359159651},{"date":"2025-10-03","current":-19.179371,"twenty":-27.951558,"median":-26.814509,"eighty":-23.612343,"marketCap":4545323379},{"date":"2025-10-10","current":-18.42629,"twenty":-27.909584,"median":-26.722604,"eighty":-23.450061,"marketCap":4360487033}],"updateTime":1760393503435},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"02561\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2575741574","title":"维升药业-B(02561)：陆楹已获委任为首席财务官","url":"https://stock-news.laohu8.com/highlight/detail?id=2575741574","media":"智通财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575741574?lang=zh_cn&edition=fundamental","pubTime":"2025-10-13 17:54","pubTimestamp":1760349298,"startTime":"0","endTime":"0","summary":"智通财经APP讯，维升药业-B(02561)发布公告，陆楹已获委任为公司首席财务官，自2025年10月13日起生效。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1354329.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","02561"],"gpt_icon":0},{"id":"2575684402","title":"维升药业-B10月13日主力净流出23.9万元 散户资金买入","url":"https://stock-news.laohu8.com/highlight/detail?id=2575684402","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575684402?lang=zh_cn&edition=fundamental","pubTime":"2025-10-13 16:15","pubTimestamp":1760343352,"startTime":"0","endTime":"0","summary":"10月13日, 维升药业-B股价跌1.40%，报收40.94元，成交金额126.9万元，换手率0.03%，振幅3.08%，量比0.98。维升药业-B今日主力资金净流出23.9万元，上一交易日主力净流出0万元。该股近5个交易日下跌5.80%，主力资金累计净流出75.7万元；近20日主力资金累计净流出361.7万元，其中净流出天数为7日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251013162107972ad22d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251013162107972ad22d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","02561"],"gpt_icon":0},{"id":"2574135261","title":"维升药业-B10月09日主力净流出51.8万元 散户资金买入","url":"https://stock-news.laohu8.com/highlight/detail?id=2574135261","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2574135261?lang=zh_cn&edition=fundamental","pubTime":"2025-10-09 16:15","pubTimestamp":1759997744,"startTime":"0","endTime":"0","summary":"10月09日, 维升药业-B股价跌2.95%，报收42.70元，成交金额159.7万元，换手率0.03%，振幅3.68%，量比1.16。维升药业-B今日主力资金净流出51.8万元，上一交易日主力净流出0万元。该股近5个交易日上涨0.47%，主力资金累计净流出51.8万元；近20日主力资金累计净流出337.8万元，其中净流出天数为6日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251009161951a6b1a6da&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251009161951a6b1a6da&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","02561"],"gpt_icon":0},{"id":"2573362583","title":"维升药业-B午前涨超3% 隆培促生长素有望年内获批上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2573362583","media":"新浪港股","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2573362583?lang=zh_cn&edition=fundamental","pubTime":"2025-10-06 11:42","pubTimestamp":1759722120,"startTime":"0","endTime":"0","summary":"　　维升药业-B午前股价上涨3.08%，现报44.80港元，成交额104.211万港元。　　根据维升药业招股书，公司研发进展最快的是隆培促生长素，公司预计在2025下半年国内获批上市，有望成为国内第三款上市的长效生长激素。今年7月，维升又与安科生物达成合作，共同推进产品的商业化，未来市场前景值得期待。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2025-10-06/doc-infsxkpt2665338.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["02561","BK1161"],"gpt_icon":0},{"id":"2572522775","title":"创新药全链条高景气持续，维升药业-B(02561)或迎“戴维斯双击”","url":"https://stock-news.laohu8.com/highlight/detail?id=2572522775","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2572522775?lang=zh_cn&edition=fundamental","pubTime":"2025-10-03 08:55","pubTimestamp":1759452900,"startTime":"0","endTime":"0","summary":"在港股创新药“差异化兑现”周期中，市场积极寻求既有“估值修复+产品兑现”双重逻辑，又兼具业绩确定性与长期成长空间的稀缺投资标的，维升药业-B或属其中。据了解，维升药业致力于提供同类首创或同类最优的内分泌疾病产品和治疗方案。站在当前时点，创新药企业估值重构的核心在于“产品兑现能力”，维升药业核心产品即将进入商业化阶段的优势，在当前“盈利驱动”的板块逻辑中尤为突出。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1352043.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["159992","BK1574","BK1161","02561","06978"],"gpt_icon":0},{"id":"2569775672","title":"维升药业-B09月23日遭主力抛售21.5万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2569775672","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2569775672?lang=zh_cn&edition=fundamental","pubTime":"2025-09-23 16:16","pubTimestamp":1758615365,"startTime":"0","endTime":"0","summary":"09月23日, 维升药业-B股价跌1.66%，报收42.70元，成交金额122.7万元，换手率0.03%，振幅2.12%，量比0.87。维升药业-B今日主力资金净流出21.5万元，上一交易日主力净流出57.1万元。该股近5个交易日下跌6.11%，主力资金累计净流出78.6万元；近20日主力资金累计净流入11.5万元，其中净流入天数为1日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250923163752a7312fae&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250923163752a7312fae&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","02561"],"gpt_icon":0},{"id":"2569275790","title":"大摩：市场对生物科技股认可度提升 推动股价跑赢大市 看好康方生物(09926)等","url":"https://stock-news.laohu8.com/highlight/detail?id=2569275790","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2569275790?lang=zh_cn&edition=fundamental","pubTime":"2025-09-23 09:47","pubTimestamp":1758592020,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，摩根士丹发布研报称，在港上市的中国生物科技股总市值由年初至今累升154%，远超恒指同期的34%升幅，相信是反映了市场对本土药企创新能力的认可度发生重大转变，预期美联储加快减息步伐将推动风险偏好调整，推动资金流向中国生物科技等增长型板块。惟大摩预期，个别股分表现仍取决于公司基本面，包括商业化执行力及创新研发进度，看好具短期催化剂的公司，如康方生物(09926)、诺诚健华(09969)、和誉-B(02256)、信达生物(01801)、映恩生物-B(09606)等，另外亦给予维升药业-B(02561)及再鼎医药(09688)“跑赢大市”评级。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1348283.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","HK0000252160.HKD","09926","LU0417516902.SGD","LU2543165471.USD","LU0502904849.HKD","HK0000252152.HKD","LU0348784397.USD","LU0348827113.USD","LU0348735423.USD","01801","09606","LU2488822045.USD","IE00B5MMRT66.SGD","BK1583","LU2097828714.EUR","159837","LU1969619763.USD","LU2242644610.SGD","LU2476274720.SGD","LU1794554557.SGD","LU2097828631.EUR","LU2097828557.USD","LU1720050803.USD","LU2476274308.USD","LU0348825331.USD","HK0000500386.USD","LU2778985437.USD","02561","LU2328871848.SGD","BK1589","LU0348766576.USD","IE00BPRC5H50.USD","BK1574","02256","IE00B543WZ88.USD","LU0455707207.USD","09969","LU2097828805.USD","LU0540923850.HKD","LU2097828474.EUR","LU0634319403.HKD","LU0417516738.SGD","LU0417516571.SGD","LU0348767384.USD","LU0561508036.HKD","LU0348783233.USD"],"gpt_icon":0},{"id":"2569758685","title":"维升药业-B09月22日主力净流出57.1万元 散户资金买入","url":"https://stock-news.laohu8.com/highlight/detail?id=2569758685","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2569758685?lang=zh_cn&edition=fundamental","pubTime":"2025-09-22 16:15","pubTimestamp":1758528922,"startTime":"0","endTime":"0","summary":"09月22日, 维升药业-B股价跌1.14%，报收43.42元，成交金额161.0万元，换手率0.03%，振幅1.87%，量比1.21。维升药业-B今日主力资金净流出57.1万元，上一交易日主力净流出0万元。该股近5个交易日下跌1.94%，主力资金累计净流入33.0万元；近20日主力资金累计净流入33.0万元，其中净流入天数为1日。该股主力净额占比0.01%，港股市场排名2345/2670。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250922161642a72ee976&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250922161642a72ee976&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02561","BK1161"],"gpt_icon":0},{"id":"2567105050","title":"维升药业-B09月16日主力净流入90.1万元 散户资金抛售","url":"https://stock-news.laohu8.com/highlight/detail?id=2567105050","media":"市场透视","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2567105050?lang=zh_cn&edition=fundamental","pubTime":"2025-09-16 16:16","pubTimestamp":1758010568,"startTime":"0","endTime":"0","summary":"09月16日, 维升药业-B股价涨2.71%，报收45.48元，成交金额327.7万元，换手率0.06%，振幅5.87%，量比5.92。维升药业-B今日主力资金净流入90.1万元，上一交易日主力净流出0万元。该股近5个交易日上涨0.40%，主力资金累计净流入90.1万元；近20日主力资金累计净流入64.0万元，其中净流入天数为1日。该股主力净额占比0.02%，港股市场排名271/2670。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025091616241097959d25&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025091616241097959d25&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02561","BK1161"],"gpt_icon":0},{"id":"2567812269","title":"横盘迷雾下的价值火山：维升药业-B（2561.HK）正站在价值重构临界点","url":"https://stock-news.laohu8.com/highlight/detail?id=2567812269","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2567812269?lang=zh_cn&edition=fundamental","pubTime":"2025-09-16 10:02","pubTimestamp":1757988142,"startTime":"0","endTime":"0","summary":"当一款重磅产品进入商业化倒计时，当全链条战备已搭建完毕，这种僵持注定只是暴风雨前的宁静，维升药业也正面临价值重估的关键节点。","market":"fut","thumbnail":"https://img7.gelonghui.com/column/2.png?guru_height=540&guru_width=375","type":0,"news_type":0,"thumbnails":["https://img7.gelonghui.com/column/2.png?guru_height=540&guru_width=375"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/p/2840463","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"gelonghui_highlight","symbols":["02561","BK1161"],"gpt_icon":0},{"id":"2564866024","title":"长效生长激素“元年”启幕，从“日剂”到“周剂”百亿市场竞争格局生变","url":"https://stock-news.laohu8.com/highlight/detail?id=2564866024","media":"动脉网","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2564866024?lang=zh_cn&edition=fundamental","pubTime":"2025-09-01 08:02","pubTimestamp":1756684948,"startTime":"0","endTime":"0","summary":"国内长效生长激素市场正逐渐从单一参与者变为维升药业、特宝生物、金赛药业、安科生物、诺和诺德等多方竞争的格局。弗若斯特沙利文数据显示，预计国内长效生长激素市场规模将在两年内超过短效生长激素，并在2030年占据生长激素全市场73.8%。相比于国内GLP-1长效制剂百条管线激烈角逐的盛况，长效生长激素的竞争相对缓和。据梳理，过往在长效生长激素研发过程中“摔跟头”的企业不在少数。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250901080521a4abf309&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250901080521a4abf309&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1093756168.USD","BK4599","NVO","BK4208","IE00BKVL7J92.USD","IE00BD4GTT62.SGD","O","IE00BMG7P819.SGD","IE00BD4GTW91.USD","IE00BMG7P926.USD","LU0154236417.USD","LU1093756325.SGD","02561","IE00BMG7P694.USD","PEG","BK4532","IE00BZ1G4Q59.USD","BK4007","BK4588","BK4585","IE00BMG7P587.USD","IE00BD4GTV84.USD","LU2346227817.USD"],"gpt_icon":1},{"id":"2562433740","title":"维升药业-B(02561)发布中期业绩 研究及开发成本4662.1万元 同比增加19.8%","url":"https://stock-news.laohu8.com/highlight/detail?id=2562433740","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2562433740?lang=zh_cn&edition=fundamental","pubTime":"2025-08-27 22:45","pubTimestamp":1756305931,"startTime":"0","endTime":"0","summary":"于2023年12月，集团与药明生物订立了合作协议，据此，药明生物将作为技术转移的本地CDMO 进行工艺开发和验证，实现生产技术的本地化。截至2025年6月，已完成关键试剂及中间体的技术转移小试研发，集团的目标是在2025年年末或之前完成核心产品原液的技术转移小试研发，全部技术转移及本地化预计将于2027 年完成，届时将赋予集团与药明生物合作生产核心产品药物原液的技术能力。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1336733.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","02561"],"gpt_icon":0},{"id":"2557517316","title":"Ascendis 上半年产品收入大涨 155%，维升药业拥有国内权益","url":"https://stock-news.laohu8.com/highlight/detail?id=2557517316","media":"Insight数据库","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2557517316?lang=zh_cn&edition=fundamental","pubTime":"2025-08-08 12:31","pubTimestamp":1754627499,"startTime":"0","endTime":"0","summary":"当地时间 8 月 7 日，维升药业合作伙伴 Ascendis Pharma 发布了 2025 年第二季度和上半年业绩报告。第二季度，该公司营收为 1.58 亿欧元，同比大涨 339%；上半年总营收为 2.59 亿欧元，同比增长 96%。两款商业化产品上半年总计创收 2.5 亿欧元，同比大涨 155%。维升药业拥有帕罗培特立帕肽、隆培生长激素、那韦培肽的大中华区权益。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250808123424a47c5cb4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250808123424a47c5cb4&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","02561"],"gpt_icon":1},{"id":"2555884192","title":"维升药业-B07月31日遭主力抛售37.4万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2555884192","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2555884192?lang=zh_cn&edition=fundamental","pubTime":"2025-07-31 16:15","pubTimestamp":1753949747,"startTime":"0","endTime":"0","summary":"07月31日, 维升药业-B股价跌5.31%，报收49.00元，成交金额454.0万元，换手率0.08%，振幅5.41%，量比1.12。维升药业-B今日主力资金净流出37.4万元，上一交易日主力净流出39.0万元。该股近5个交易日上涨2.52%，主力资金累计净流入23.4万元；近20日主力资金累计净流入191.4万元，其中净流入天数为3日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250731170829a46d36a1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250731170829a46d36a1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","02561"],"gpt_icon":0},{"id":"2555994950","title":"维升药业－Ｂ(02561)股价上升5.07%，现价港币$52.85","url":"https://stock-news.laohu8.com/highlight/detail?id=2555994950","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2555994950?lang=zh_cn&edition=fundamental","pubTime":"2025-07-30 11:25","pubTimestamp":1753845900,"startTime":"0","endTime":"0","summary":"[上升股]维升药业－Ｂ(02561) 股价在上午11:25比前收市价上升5.07%，现股价为港币$52.85。至目前为止，今日最高价为$52.85，而最低价为$50.3。总成交量为7.03万股，总成交金额为港币$365.179万。","market":"other","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180725133914771_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180725133914771_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAR2507301172/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1161","02561"],"gpt_icon":0},{"id":"2555609141","title":"用于成人！长效生长激素获 FDA 批准上市，维升药业拥有国内权益","url":"https://stock-news.laohu8.com/highlight/detail?id=2555609141","media":"Insight数据库","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2555609141?lang=zh_cn&edition=fundamental","pubTime":"2025-07-30 10:36","pubTimestamp":1753842978,"startTime":"0","endTime":"0","summary":"此前该药已获得 FDA 批准用于治疗儿童 GHD 患者。此次获批的成人 GHD 适应症主要基于 foresiGHt 试验的结果，该试验旨在对比每周一次 TransCon hGH 疗法与每周一次安慰剂及每日一次阳性对照药物在成人 GHD 患者中的有效性与安全性。TransCon hGH 已以商品名 Skytrofa 获美国 FDA 与欧盟 EMA 批准，是欧美首个每周一次给药的长效生长激素，用于治疗儿童及青少年 GHD。2024 年 8 月，中国 NMPA 受理其儿童 GHD 适应症上市申请。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250730110328a46aaebe&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250730110328a46aaebe&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","02561"],"gpt_icon":0},{"id":"2554776887","title":"维升药业-B07月28日主力净流入99.8万元 散户资金抛售","url":"https://stock-news.laohu8.com/highlight/detail?id=2554776887","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2554776887?lang=zh_cn&edition=fundamental","pubTime":"2025-07-28 16:15","pubTimestamp":1753690543,"startTime":"0","endTime":"0","summary":"07月28日, 维升药业-B股价涨4.39%，报收51.15元，成交金额616.9万元，换手率0.11%，振幅4.90%，量比0.86。维升药业-B今日主力资金净流入99.8万元，上一交易日主力净流出0万元。该股近5个交易日上涨7.57%，主力资金累计净流入104.0万元；近20日主力资金累计净流入221.5万元，其中净流入天数为3日。该股主力净额占比0.02%，港股市场排名273/2673。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250728165529a6c5a266&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250728165529a6c5a266&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","02561"],"gpt_icon":0},{"id":"2553372002","title":"维升药业-B07月22日主力净流出32.9万元 散户资金买入","url":"https://stock-news.laohu8.com/highlight/detail?id=2553372002","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2553372002?lang=zh_cn&edition=fundamental","pubTime":"2025-07-22 16:15","pubTimestamp":1753172143,"startTime":"0","endTime":"0","summary":"07月22日, 维升药业-B股价跌1.58%，报收46.80元，成交金额343.3万元，换手率0.06%，振幅3.79%，量比0.55。维升药业-B今日主力资金净流出32.9万元，上一交易日主力净流入196万元。该股近5个交易日上涨2.74%，主力资金累计净流入163.1万元，其中1个交易日为股价下跌时净流入；近20日主力资金累计净流入80.6万元，其中净流入天数为2日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250722170216a45be5f9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250722170216a45be5f9&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","02561"],"gpt_icon":0},{"id":"2551137423","title":"维升药业-B(02561)携手安科生物 加速长效生长激素中国商业化进程","url":"https://stock-news.laohu8.com/highlight/detail?id=2551137423","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2551137423?lang=zh_cn&edition=fundamental","pubTime":"2025-07-15 10:19","pubTimestamp":1752545983,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，维升药业-B7月14日宣布与安科生物签订战略合作框架协议。在合作期限内，维升药业授权安科生物在中国境内特定区域内排他性独家推广隆培促生长素产品。维升药业与安科生物成功牵手，双方围绕隆培促生长素展开的业务也有望完善安科生物在生长激素方面的布局，实现全剂型覆盖，凭借维升药业创新助力冲击中国市场。该产品目前已在美国及欧洲获批上市，预计2025年内在中国获批，计划在2028年将实现本地化商业生产。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1317772.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","02561","BK0060","BK0070","BK0239","BK0042","300009"],"gpt_icon":0},{"id":"2550683564","title":"“IPO盛宴”强势回归","url":"https://stock-news.laohu8.com/highlight/detail?id=2550683564","media":"艾美达医药咨询","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2550683564?lang=zh_cn&edition=fundamental","pubTime":"2025-07-09 15:00","pubTimestamp":1752044427,"startTime":"0","endTime":"0","summary":"2025年7月1日，上交所官网显示，武汉禾元生物科技股份有限公司科创板IPO成功通过上交所上市审核委员会审议，成为科创板第五套上市标准重启后首家过会的IPO企业。2025年的A股生物医药IPO市场呈现出积极且结构化的新格局。亦诺微医药、微脉、百力司康等数十家医健企业已向港交所递交上市申请，排队等候上市，场面火爆，预示着下半年IPO热潮将持续。此外，多个IPO项目获得投资者热烈追捧。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250709150735a69ec54e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250709150735a69ec54e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02592","LU1328615791.USD","LU2488822045.USD","600276","LU2495084118.USD","BK0012","02561","01877","LU0405327148.USD","01801","BK0188","BK0239","LU1997244956.HKD","LU1997245094.SGD","LU1064131003.USD","LU1655091616.SGD","02617","LU1969619763.USD","159982","LU1064130708.USD","LU2328871848.SGD","BK0196","LU1997245177.USD","LU2148510915.USD","BK0028","BK0183","BK0060","LU0405327494.USD"],"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":1,"totalSize":51,"code":"91000000","status":"200"}]}}